Combination of alendronate and genistein synergistically suppresses osteoclastic differentiation of RAW267.4 cells \textit{in vitro}

MASAYOSHI YAMAGUCHI$^1$ and ROBERT M. LEVY$^2$

$^1$Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA 30322; $^2$Department of Clinical Development, Primus Pharmaceuticals, Inc., Scottsdale, AZ 85253, USA

Received November 12, 2016; Accepted March 3, 2017

DOI: 10.3892/etm.2017.4695

Abstract. Bone is a dynamic tissue that undergoes constant remodeling, with removal by osteoclastic bone resorption and replacement via osteoblastic bone formation and mineralization. Deterioration of bone mass with aging leads to osteoporosis. Bisphosphonates are potent inhibitors of osteoclastic bone resorption. Genistein, an isoflavone, exerts a bone anabolic effect by suppressing osteoclastic bone resorption and stimulating osteoblastic bone formation. The present study was undertaken to investigate the anabolic effects of a combination of alendronate and genistein on osteoclastic differentiation. Preosteoclastic RAW267.4 cells were cultured with alendronate (0.1-100 µM) and/or genistein (0.1-100 µM) \textit{in vitro}. Alendronate or genistein alone had no significant effect on the proliferation and death of RAW267.4 cells. Notably, the combination of the two agents was found to potently and synergistically repress the proliferation and death of RAW267.4 cells. Moreover, alendronate or genistein used separately at higher concentrations suppressed the osteoclastic differentiation of RAW267.4 cells induced by receptor activator of nuclear factor-κB ligand (RANKL) \textit{in vitro}. However, combinations of the two agents (0.1-100 µM) synergistically suppressed the RANKL-induced osteoclastic differentiation. In conclusion, bisphosphonate and genistein combination therapy may provide a novel strategy for the prevention and treatment of osteoclastic bone resorption.

Introduction

Bone homeostasis is regulated through the functions of osteoclasts and osteoblasts (1-3). Bone is a dynamic tissue constantly remodeled by the sequential removal (bone resorption) of mature tissue by osteoclasts and its replacement (bone formation) through the deposition of newly formed mineralized matrix by osteoblasts (1-3). Osteoclasts are derived from hematopoietic progenitor cells and osteoblasts develop from bone marrow mesenchymal stem cells (1,2). Bone homeostasis is maintained through the actions of various hormones, cytokines and bone marrow environmental systems (1-3). This disturbance induces bone loss (1). Aging leads to osteoporosis associated with a deterioration of bone mass through suppressed bone formation and promoted bone resorption (4,5). Osteoporosis is widely recognized as a major public health problem (4,5). A notable manifestation of this disease is fracture of the proximal femur, the incidence of which increases as the population ages (4,5). Decreased bone mass in females is primarily due to reduced secretion of estrogen following the beginning of the menopause (5). Osteoporosis is an important cause of morbidity and mortality in elderly women. Development of a new supplemental strategy will be useful in the prevention and treatment of osteoporosis.

Bisphosphonates are a group of drugs that have a structural similarity to pyrophosphate, a high affinity for mineralized tissue, and were developed as agents for inhibiting osteoclastic bone resorption (6,7). These drugs have often been used as the first treatment option for osteoporosis since 1960s, when the first bisphosphonates were developed as drugs for human use (6,7). There are two main classes of bisphosphonates which differ in potency and mode of action, namely the low potency, non-nitrogen-containing bisphosphonates including coronate and tinate, and the more commonly used higher potency, nitrogen-containing bisphosphonates including alendronate, ibandronate and zoledronate (6,7). Bisphosphonates are widely used for their multimodal bone-sparing action to prevent and treat osteoporosis in postmenopausal women, bone pain and hypercalcemia of malignancy (6,8,9). Oral bisphosphonates such as alendronate, risedronate and etidronate are used beneficially to reduce the risk of skeletal fractures in patients with osteoporosis and in metastatic bone cancer (10). However, recent studies have suggested that the inhibitory effects of bisphosphonates on osteoclasts lead to impaired bone remodeling, bisphosphate-related osteonecrosis of the jaw, gastrointestinal side effects and risk of cancer (11-13).

Botanical isoflavones, including daidzin, daidzein, genistein and genin, are contained at relatively high concentrations in soybeans (14,15). Daidzin and genistin are hydrolyzed to
daidzein and genistein, respectively, by β-glucosidase in the gastrointestinal tract (14,15). Among isoflavones, genistein has been demonstrated to have potent direct anabolic effects on bone metabolism in vitro (14-20), suggesting a role in the prevention of osteoporosis. Therefore, it is hypothesized that genistein may be useful in the prevention and treatment of osteoporosis.

The present study was undertaken to determine whether the bisphosphonate alendronate and the isoflavone genistein synergistically suppress osteoclastic differentiation using preosteoclastic RAW267.4 cells in vitro. The combination of alendronate and genistein was found to exhibit a synergistic suppressive effect on osteoclastic differentiation in vitro. Thus, such combinations may provide a new strategy for the prevention and treatment of osteoporosis with reduced bisphosphonate toxicity.

Materials and methods

Materials and cells. Dulbecco’s Modification of Eagle’s Medium (DMEM) with 4.5 g/l glucose, L-glutamine, sodium pyruvate and antibiotics [penicillin and streptomycin (P/S)] was purchased from Mediatech, Inc. (Corning, Manassas, VA, USA). Fetal bovine serum (FBS) was from Hyclone (GE Healthcare Life Sciences, Logan, UT, USA). Alendronate, genistein, leukocyte acid phosphatase kits for tartrate resistant acid phosphatase (TRAP) staining and all other reagents were purchased from Sigma-Aldrich (Merck KGaA, Darmstadt, Germany) unless otherwise specified. The receptor activator of nuclear factor-κB ligand (RANKL) was from R&D Systems, Inc. (Minneapolis, MN, USA). Reagents were dissolved in 100% ethanol and sterilized distilled water. Mouse monocytic RAW267.4 cells were obtained from the American Type Culture Collection (Rockville, MD, USA) (21,22).

Cell proliferation. RAW267.4 cells (1x10^6/ml cells/well; 2 ml medium added per well in 24-well plates) were cultured in DMEM containing 10% FBS and 1% P/S for 3 days in a water-saturated atmosphere containing 5% CO_2 and 95% air at 37°C (23). The cells were then cultured in DMEM containing 10% FBS and 1% P/S in the presence or absence of vehicle (ethanol; final concentration 0.1%), alendronate (0.1, 1, 10 or 100 µM), genistein (0.1, 1, 10 or 100 µM), or alendronate (0.1, 1, 10 or 100 µM) plus genistein (0.1, 1, 10 or 100 µM). After culture, cells were detached from each culture dish and counted as described for the cell proliferation assay.

Osteoclastogenesis assays and TRAP staining. RAW264.7 cells were cultured in 96-well plates in DMEM supplemented with 10% FBS and 1% P/S at a density of 1x10^4 cells/well. Cells were cultured for 6 days with RANKL (30 ng/ml) pre-incubated for 10 min with crosslinking anti-poly-histidine antibody (2.5 µg/ml; IC050P; R&D Systems, Inc., Minneapolis, MN, USA) to induce osteoclast formation (21,22), in the presence or absence of vehicle (ethanol; final concentration 0.1%), alendronate (0.1, 1, 10 or 100 µM), genistein (0.1, 1, 10 or 100 µM), or alendronate (0.1, 1, 10 or 100 µM) plus genistein (0.1, 1, 10 or 100 µM). After 6 days of culture, the cells were fixed and stained for TRAP, a specific marker of the osteoclast phenotype, using a leukocyte acid phosphatase kit. Briefly, cells were washed with PBS, fixed with 10% neutralized formalin-phosphate (pH 7.2) for 10 min, dried and stained with a leukocyte acid phosphatase kit (387A; Sigma-Aldrich; Merck KGaA, Darmstadt, Germany) for staining of tartrate resistant acid phosphatase (TRAP) at room temperature for 90 min. TRAP-positive multinucleated cells (MNCs with at least three nuclei) were considered to be osteoclast-like cells, and the cells were counted using light microscopy (Olympus MTV-3). MNC scores are expressed as the mean ± standard deviation of six cultures with two replicate wells per data set using different dishes and cell preparation.

Statistical analysis. Statistical analysis was performed using GraphPad InStat software (version 3; GraphPad Software, Inc., La Jolla, CA, USA). Multiple comparisons were performed by one-way analysis of variance, followed by a post hoc Tukey’s range test for parametric data. P<0.05 was considered to indicate a statistically significant difference.

Results

Combination of alendronate and genistein reveals a synergistic suppressive effect on the proliferation of RAW267.4 cells. The effects of the bone metabolism regulators alendronate and genistein on the proliferation of RAW267.4 cells in vitro were examined. RAW267.4 cells were cultured for 3 days in the presence or absence of each compound. Culture with alendronate (0.1, 1, 10 and 100 µM) or genistein (0.1, 1, 10 and 100 µM) individually did not have a significant effect on the proliferation of RAW267.4 cells as compared with that of the control (0.1% ethanol vehicle; Fig. 1A and B). Next, the effects of various combinations of alendronate and genistein on the proliferation of RAW267.4 cells in vitro were determined. Notably, the combinations of alendronate and genistein with concentrations (0.1, 1, 10 and 100 µM) that did not independently reveal a significant effect on cell proliferation were found to synergistically suppress cell proliferation (Fig. 1C). Thus, the combination of alendronate and genistein was shown to possess a potent and synergistic suppressive effect on RAW267.4 cells in vitro.

Combination of alendronate and genistein synergistically stimulates the death of RAW267.4 cells in vitro. The effects of alendronate and genistein on the death of RAW267.4 cells in vitro were determined. Cells were cultured for 3 days until
they reached confluence, and then the cells were additionally cultured for 2 days in the presence of 0.1% ethanol, alendronate (0.1, 1.0, 10 and 100 µM) or genistein (0.1, 1.0, 10 and 100 µM). Alendronate (0.1, 1.0, 10 and 100 µM) or genistein (0.1, 1.0, 10 and 100 µM) alone did not cause a significant alteration in the number of RAW267.4 cells (Fig. 2A and B). However, combinations of alendronate (0.1, 1.0, 10 and 100 µM) and genistein (0.1, 1.0, 10 and 100 µM) significantly reduced the cell number, indicating that this combination treatment induces cell death (Fig. 2C).

Combination of alendronate and genistein synergistically suppresses osteoclast differentiation of RAW267.4 cells in vitro. To establish an in vitro osteoclastogenesis model suitable for investigation of the activity of combined alendronate and genistein, RAW264.7 monocytic cells were induced to differentiate into osteoclasts by the addition of the key osteoclastogenic cytokine RANKL (2,3). The effects of alendronate and genistein on osteoclast differentiation were tested over a dose range from 0.1 to 100 µM; the cultures were stained with TRAP 6 days later and osteoclast formation was quantified. RANKL induced robust osteoclast formation (Fig. 3). Culture with alendronate (0.1, 1.0 and 10 µM) alone had no significant effect on the RANKL-induced enhancement of osteoclastic differentiation (Fig. 3A). Genistein (0.1 and 1.0 µM) also did not reveal an effect on RANKL-stimulated osteoclastic differentiation. However, this stimulatory effect of RANKL was suppressed by addition of higher concentrations of alendronate (100 µM; Fig. 3A) and genistein (10 and 100 µM; Fig. 3B). Notably, the combinations of alendronate (0.1, 1.0, 10 and 100 µM) and genistein (0.1, 1.0, 10 and 100 µM) were found to exhibit synergistic suppressive effects on the RANKL-induced enhancement of osteoclastogenesis in RAW267.4 cells in vitro (Fig. 3C).

Discussion

The present study demonstrates the ability of combination of alendronate and genistein to synergistically suppress the proliferation and stimulate the death of preosteoclastic RAW264.7 murine monocytic cells in vitro. Moreover, the combination of alendronate and genistein was found to synergistically suppress the osteoclastic differentiation enhanced by RANKL, a previously demonstrated stimulator of osteoclastic differentiation in RAW264.7 cells (21,22). To the best of our knowledge, this is novel that has not been reported previously, and it may provide a new strategy for the prevention and treatment of bone deterioration induced by osteoclastic bone resorption.
Alendronate and genistein when used separately did not show significant effects on the proliferation and death of RAW267.4 cells in vitro. Notably, the combination of the two agents acted synergistically to suppress the proliferation and increase the death of RAW267.4 cells, and subsequently suppress the differentiation of preosteoclastic RAW267.4 cells to mature osteoclasts. Furthermore, this combination exhibited a synergistic suppressive effect on RANKL-induced osteoclastic differentiation as compared with the effect of each agent. This suppressive effect on osteoclastic differentiation may be partly based on the proliferation-inhibiting and death-inducing effects of the combination on RAW267.4 cells, which decreased the number of preosteoclastic cells.

Direct effects of genistein on osteoclast precursor differentiation (25,26) and mature osteoclasts (27) have shown that, in addition to stimulating osteoblast function (20), genistein may protect bone by reducing mature osteoclast formation. These effects were observed with genistein concentrations of >10 µM (25-27). Genistein has been shown to have a potent suppressive effect at the later stage of RANKL-induced osteoclastic differentiation in mouse bone marrow cultures (17). Moreover, genistein has been shown to suppress bone resorption in bone tissue culture (16). In the present study, it was demonstrated that genistein negatively regulates the RANKL-induced osteoclastic differentiation of RAW264.7 cells in vitro.

Bisphosphonates have been shown to have a direct suppressive effect on osteoclasts (6,7,28). This effect was observed with an alendronate concentration of 100 µM, which induced the apoptosis of rabbit osteoclasts in vitro (28). In the present study, combinations of alendronate and genistein with lower concentrations were found to synergistically inhibit the RANKL-induced osteoclastic differentiation of RAW267.4 cells in vitro. These results indicate that this combination may have a potent suppressive effect on osteoclastic bone resorption. Genistein has been indicated to exhibit suppressive effects at the later stage of osteoclastic differentiation and stimulatory effects on the apoptosis of mature osteoclasts (17,25-27), and alendronate may directly stimulate the apoptosis of mature osteoclasts (16). Thus, a combination of alendronate and genistein is speculated to regulate multiple steps associated with osteoclastogenesis and mature osteoclasts. However, additional studies are required to elucidate the mechanism.

There is evidence indicating that bisphosphonate drugs have toxic effects, leading to impaired bone remodeling, bisphosphonate-related osteonecrosis of the jaw, gastrointestinal side effects and risk of cancer (11-13). The present study demonstrated that a combination comprising a relatively low effective dose of a bisphosphonate-type drug and genistein exhibits an inhibitory effect on osteoclastic differentiation. Furthermore, genistein possesses a potent stimulatory effect on osteoblastic bone formation in vitro and in vivo (15,16). The current study findings may provide a new strategy for the prevention and treatment of osteoclastic bone loss in osteoporosis. Combining alendronate with genistein may be useful for reducing the toxicity of the bisphosphonate drug, and may provide potent therapeutic effects.
In conclusion, the present study demonstrates that combinations of alendronate and genistein exhibit potent and synergistic suppressive effects on the osteoclastic differentiation of preosteoclastic RAW267.4 cells in vitro. These combinations could potentially inhibit osteoclastic bone resorption. However, further studies are required to investigate the clinical aspects.

References


